Complexed prostate-specific antigen for the diagnosis of biochemical recurrence after radical prostatectomy
- 1 April 2007
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 99 (4) , 758-761
- https://doi.org/10.1111/j.1464-410x.2007.06680.x
Abstract
To determine the validity of using complexed prostate-specific antigen (cPSA) levels for diagnosing biochemical recurrence after radical prostatectomy (RP). With linear regression modelling, we determined threshold cPSA levels for biochemical recurrence in patients after RP for clinically localized prostate cancer. We calculated sensitivity, specificity, predictive values, and likelihood ratio tests of each threshold for diagnosing biochemical recurrence using total PSA (tPSA) as the reference standard. In the regression models, tPSA and cPSA were highly correlated (r = 0.99). For the diagnosis of biochemical recurrence, tPSA thresholds of 0.20 and 0.40 ng/mL corresponded to cPSA thresholds of 0.12 ng/mL (95% confidence interval 0.08-0.17) and 0.29 (0.22-0.28) ng/mL, respectively. For the detection of biochemical recurrence, a cPSA threshold of 0.12 ng/mL had a sensitivity of 96%, specificity of 88%, positive predictive value of 89%, negative predictive value of 88%, positive likelihood ratio of 8, and negative likelihood ratio of 0.05; the respective values for a cPSA threshold of 0.29 ng/mL were 96%, 96%, 96%, 96%, 24 and 0.04. cPSA has high validity for the diagnosis of biochemical recurrence after RP. Pending external validation, cPSA might be useful for biochemical surveillance after RP.Keywords
This publication has 18 references indexed in Scilit:
- New Insights Into the Diagnostic Accuracy of Complexed and Total Prostate Specific Antigen Using Discordance Analysis CharacteristicsJournal of Urology, 2006
- The Detection and Potential Economic Value of Complexed Prostate Specific Antigen as a First Line TestJournal of Urology, 2006
- Complexed PSA improves prostate cancer detection: Results from a multicenter Japanese clinical trialUrology, 2006
- Prostate Specific Antigen Isoforms and Human Glandular Kallikrein 2—Which Offers the Best Screening Performance in a Predominantly Black Population?Journal of Urology, 2006
- Use of Prostate-Specific Antigen (PSA) Isoforms for the Detection of Prostate Cancer in Men with a PSA Level of 2–10 ng/ml: Systematic Review and Meta-AnalysisEuropean Urology, 2005
- Complexed Prostate Specific Antigen Density is Better Than the Other PSA Derivatives for Detection of Prostate Cancer in Men with Total PSA between 2.5 and 20ng/ml: Results of a Prospective Multicenter StudyEuropean Urology, 2004
- Applying complexed prostate-specific antigen to clinical practiceUrology, 2004
- Variables in predicting survival based on treating “PSA-Only” relapseUrologic Oncology: Seminars and Original Investigations, 2003
- CAN COMPLEXED PROSTATE SPECIFIC ANTIGEN AND PROSTATIC VOLUME ENHANCE PROSTATE CANCER DETECTION IN MEN WITH TOTAL PROSTATE SPECIFIC ANTIGEN BETWEEN 2.5 AND 4.0 NG./ML.Journal of Urology, 2001
- A PROSPECTIVE STUDY TO EVALUATE THE ROLE OF COMPLEXED PROSTATE SPECIFIC ANTIGEN AND FREE/TOTAL PROSTATE SPECIFIC ANTIGEN RATIO FOR THE DIAGNOSIS OF PROSTATE CANCERJournal of Urology, 2001